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Sir, I read with great interest the article "Dramatic response to intravitreal bevacizumab in hypertensive retinopathy" by Padhy and Kumar. [1] The authors have attributed rapid resolution of intra-retinal and sub-retinal fluid at macula in both eyes following intravitreal injection of bevacizumab only in the right eye. Systemic absorption of intravitreal bevacizumab had been cited as a reason for improvement in fellow eye.
Although data on the use of bevacizumab in malignant hypertension is relatively sparse, reports on fellow eye effect of unilateral intravitreal bevacizumab in diabetic macular edema (DME) are controversial. Velez-Mentoya et al. [2] failed to identify a contralateral eye effect in a prospective study involving 23 patients. Hanhart et al. [3] have shown bilateral response after unilateral injection; however, the average reduction in central subfield macular thickness (CST) was more in injected eye and a significant proportion received multiple injections. In the index case, complete resolution of intra-and sub-retinal fluid following a single intravitreal injection can be due to systemic control of hypertension as evidenced by blood pressure (BP) at presentation and BP after 1 month. Moreover, concurrent use of systemic steroids to treat primary renal disease can also reduce blood retinal barrier breakdown and help in resolution of macular fluid.
It would be interesting to know from the authors, the magnitude of reduction in CST of injected and fellow eye and to see for any differential response between the two eyes. Symmetrical reduction in both eyes may point more toward better systemic control rather than effect of bevacizumab. Injecting bevacizumab is also known to cause dysregulation of BP especially in severe hypertensive patients. [4] Hence, using bevacizumab as a primary modality in a treatment naïve malignant hypertensive retinopathy warrants caution.
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Response to comment on: Dramatic response to intravitreal Bevacizumab in hypertensive retinopathy
Sir, We would like to thank the authors for their interest and comments on the article "Dramatic response to intravitreal Bevacizumab in Hypertensive Retinopathy" [1, 2] and address their queries as follows:
As mentioned by the authors, fellow eye effect of unilateral intravitreal Bevacizumab is controversial and the factors on which it depends are unknown. [3] It is therefore difficult to predict the effect on the fellow eye after unilateral intravitreal Bevacizumab. We noticed a significant reduction of intraretinal and subretinal fluid in both the eyes at 1 week after unilateral intravitreal Bevacizumab injection, while the blood pressure (BP) was still not well controlled. Since the patient was started on oral steroids 1 month back (as per advice of the treating nephrologist) and developed severe hypertensive retinopathy during this period, it is unlikely that systemic steroids would have contributed toward resolution of intraretinal and subretinal fluid. All these factors point toward the effect of intravitreal Bevacizumab on the fellow eye. Nevertheless, it is difficult to exclude the additional effect of hypertension control at 1 month on the resolution of macular edema.
The pre-injection central subfield macular thickness (CST) was 695 microns in OD and 591 microns in OS. At 1-month post injection, it was 301 microns in OD and 282 microns in OS.
We agree with the authors that intravitreal Bevacizumab may cause dysregulation of BP, especially in severely hypertensive patients. [4] However, the rise in BP after intravitreal Bevacizumab is usually mild and is considered to be safe even in hypertensive patients. [5, 6] Furthermore, our patient was under close observation in our institution's nephrology and cardiology departments and due clearance had been obtained prior to the injection.
The dramatic anatomical and functional response to intravitreal Bevacizumab in our patient reinforces that this maybe a viable option to avoid irreversible vision loss from macular edema in hypertensive retinopathy. Collaboration with cardiology and nephrology departments for BP control and subsequent monitoring is warranted in such patients.
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